pamidronate has been researched along with Hematologic Malignancies in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Specific treatment of cancer remains essential to prevent TIH relapse." | 2.41 | [Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. ( Lortholary, A, 2001) |
| "Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)." | 1.42 | Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gabbert, TI | 1 |
| Hoffmeister, B | 1 |
| Felsenberg, D | 1 |
| Lortholary, A | 1 |
1 review available for pamidronate and Hematologic Malignancies
| Article | Year |
|---|---|
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematolog | 2001 |
1 other study available for pamidronate and Hematologic Malignancies
| Article | Year |
|---|---|
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem | 2015 |